Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMDP-04
- Development stage
- Preclinical
- Lead developer
- NMD Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NMDP-04 is a preclinical-stage small molecule inhibitor of the skeletal muscle-specific chloride channel ClC-1, currently under development by NMD Pharma. The ClC-1 channel is primarily responsible for maintaining the resting membrane conductance of skeletal muscle fibers; its inhibition increases the excitability of the muscle fiber membrane. This mechanism is designed to compensate for impaired neuromuscular transmission, thereby improving muscle strength and reducing fatigue. NMDP-04 is being investigated for the treatment of rare neuromuscular diseases where muscle excitability is compromised.
02
Targets
CLCN1 (CLC-1)
Beyond the preview
Go deeper on NMDP-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMDP-04.